Brandon J. Blue

Hematology | Oncology

12902 Usf Magnolia Dr
Tampa, FL 33612

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Correction: Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.

Correction: Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.

Journal: Journal of cancer education : the official journal of the American Association for Cancer Education

Published: June 19, 2026

Geographic Variation and Inequities in Burden and Access to CAR T-Cell Therapies for Multiple Myeloma in the US.

Geographic Variation and Inequities in Burden and Access to CAR T-Cell Therapies for Multiple Myeloma in the US.

Journal: Clinical lymphoma, myeloma & leukemia

Published: May 18, 2026

The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma.

The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma.

Journal: American journal of hematology

Published: February 20, 2026

Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.

Understanding Physician Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.

Journal: Journal of cancer education : the official journal of the American Association for Cancer Education

Published: January 04, 2026

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma.

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma.

Journal: Bone marrow transplantation

Published: November 07, 2025

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Journal: Blood cancer journal

Published: November 04, 2025

Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: Differences by race and ethnicity.

Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: Differences by race and ethnicity.

Journal: Blood advances

Published: October 30, 2025

Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: differences by race and ethnicity.

Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: differences by race and ethnicity.

Journal: Blood advances

Published: October 30, 2025

Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma.

Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma.

Journal: Blood

Published: September 29, 2025

Actionable Steps to Address Disparities in Healthcare Among US Patients With Multiple Myeloma: A Patient Perspective.

Actionable Steps to Address Disparities in Healthcare Among US Patients With Multiple Myeloma: A Patient Perspective.

Journal: Journal of cancer education : the official journal of the American Association for Cancer Education

Published: September 11, 2025

Dermatologic Adverse Effects With Elranatamab Mimicking Talquetamab.

Dermatologic Adverse Effects With Elranatamab Mimicking Talquetamab.

Journal: American journal of hematology

Published: August 05, 2025

Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease.

Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease.

Journal: Frontiers in oncology

Published: July 11, 2025

Showing 1-12 of 34

Last Updated: 09/26/2026